2seventy bio, Inc. (NASDAQ:TSVT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of 2seventy bio, Inc. (NASDAQ:TSVT) have been given a consensus recommendation of “Moderate Buy” by the six brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $7.20.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 2seventy bio in a research note on Friday.

2seventy bio Stock Performance

Shares of NASDAQ:TSVT opened at $2.66 on Monday. The company has a market capitalization of $137.22 million, a PE ratio of -1.43 and a beta of 1.73. The company’s fifty day moving average is $2.60 and its 200-day moving average is $3.70. 2seventy bio has a 52 week low of $2.29 and a 52 week high of $5.99.

Hedge Funds Weigh In On 2seventy bio

Institutional investors have recently modified their holdings of the stock. BBR Partners LLC grew its stake in shares of 2seventy bio by 620.0% during the third quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock valued at $850,000 after purchasing an additional 155,000 shares during the last quarter. Geode Capital Management LLC lifted its holdings in 2seventy bio by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock worth $5,553,000 after buying an additional 13,144 shares in the last quarter. GSA Capital Partners LLP acquired a new position in 2seventy bio during the 3rd quarter worth $64,000. FMR LLC boosted its position in 2seventy bio by 22.0% in the 3rd quarter. FMR LLC now owns 148,545 shares of the company’s stock valued at $701,000 after buying an additional 26,738 shares during the last quarter. Finally, State Street Corp boosted its holdings in 2seventy bio by 1.5% in the third quarter. State Street Corp now owns 1,058,773 shares of the company’s stock valued at $4,997,000 after acquiring an additional 15,638 shares during the last quarter. 93.90% of the stock is owned by institutional investors.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.